同等剂量喹硫平治疗精神分裂症的血药浓度与临床疗效的关系 |
投稿时间:2011-10-24 修订日期:2012-03-05 点此下载全文 |
引用本文:段迪,凌迎春,周月琴,王玲英.同等剂量喹硫平治疗精神分裂症的血药浓度与临床疗效的关系[J].药学实践杂志,2012,30(3):218~219 |
摘要点击次数: 2268 |
全文下载次数: 742 |
|
|
中文摘要:目的 研究喹硫平同等剂量治疗精神分裂症时的稳态血药浓度与临床疗效间的关系。 方法 以固定剂量喹硫平(600 mg/d)治疗148例精神分裂症患者,疗效和不良反应采用简明精神病评定量表(BPRS)和副反应量表(TESS)进行评定,同时测定治疗第2、4、8周的稳态血清药物浓度。 结果 精神分裂症患者的BPRS减分率与血药浓度之间差异有显著性(P<0.05),血药浓度与不良反应(TESS分值)之间差异无显著性(P>0.05)。 结论 喹硫平的血药浓度检测有助于确定药物有效浓度 |
中文关键词:精神分裂症 喹硫平 血药浓度 临床疗效 |
|
The relationship between plasma concentration and clinical efficacy of quetiapine in treatment of schizophrenia with the same dose |
|
|
Abstract:Objective To study the relationship between steady-state plasma concentration and clinical efficacy of quetiapine in treatment of schizophrenia with the same dose. Methods 148 schizophrenia patients were treated with quetiapine with the same dose (600 mg/d). The clinical efficacy and adverse reactions were evaluated with BPRS and TESS respectively, while the plasma concentration of quetiapine was tested at 2nd, 4th and 8th weekend. Results The plasma concentration of quetiapine had significant difference with the reduced rate of BPRS (P<0.05), but had no difference with the scores of TESS. Conclusions The testing of plasma concentration could help to distinguish the effective and toxic concentration of quetiapine in treatment of schizophrenia, which could help doctors to choose rational dose of quetiapine for each patients. |
keywords:schizophrenia quetiapine plasma concentration clinical efficacy |
查看全文 查看/发表评论 下载PDF阅读器 |
|
关闭 |